SOURCE: BioMedReports

BioMedReports

September 15, 2009 09:19 ET

CEL-SCI's H1N1 Treatment and Vaccines Getting Some Attention From U.S. Government

PASADENA, CA--(Marketwire - September 15, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special investigative report on CEL-SCI Corporation (NYSE Amex: CVM).

According to the report, the company had been in discussions over the past several days with multiple government groups interested in expediting CEL-SCI's H1N1 efforts.

Contacted about the developments, CEL-SCI's CEO Geert Kersten made it clear that he was not able to comment on the nature or scope of any of these meetings.

When asked about recent SEC filings that shows that the company has been working not only influenza vaccines using their patented L.E.A.P.S.™ technology, but also some treatment options for already infected patients, Kersten shed more light on the situation:

"Everything here is done by collaboration. That's the idea of the team. It may have been someone's comment leading to the input of others and that took us down the road of the mutated virus and then we said, 'Well, if we can work on the mutated virus, who is actually addressing the issue of all those people lying in an ICU today, fighting for their lives for a week or ten days?' And then we figured out that using the same approach we ought to be able to help them improve their chances of survival.

"Somewhere along the way, it was like a Eureka moment," explains Kersten. "We've got to help these people. Everybody's focus is on vaccines and they're having all kinds of problems with the vaccines, but there has to be someone working to help these patients who have a high likelihood of death. That's how we got to that.

"With L.E.A.P.S.™ we can control in advance and determine, almost by design, how the immune system will process the epitope and therefore we know what kind of immune response we will get -- whether cellular or humoral. By doing that, you can -- we feel -- have significant impact on these people's chances of survival."

The complete special report authored by BioMedReport's M.E. Garza is available now at:

http://biomedreports.com/articles/most-popular/9421-cloak-and-dagger-developments-at-cel-sci-amexcvm.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content -- including FDA and Clinical Trial Calendars.

For more biomedical sector and investment news, go to www.BioMedReports.com

Contact Information

  • Mike Havrilla
    Managing Editor
    BiomedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556